
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934**

Filed by the Registrant Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Under §240.14a-12

Kiniksa Pharmaceuticals International, plc

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
 - Fee paid previously with preliminary materials.
 - Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
-
-
-

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SECOND FLOOR
105 PICCADILLY
LONDON, UNITED KINGDOM
W1J 7NJ

V90989-P50344

Your **Vote** Counts!

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC

2026 Annual General Meeting
Vote by 4:59 AM BST on May 29, 2026
(11:59 PM EDT on May 28, 2026)
or during the Annual Meeting



You invested in KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC and it's time to vote! You have the right to vote on proposals being presented at the Annual General Meeting. **This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 29, 2026.**

Get informed before you vote

View the Proxy Statement, Annual Report, UK Annual Report and other proxy materials online at www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by requesting prior to May 15, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and
vote without entering a
control number



Vote in Person at the Meeting*

May 29, 2026
2:00 PM BST (9:00 AM EDT)
Or before the Meeting vote online at
www.ProxyVote.com by 4:59 AM BST on May 29, 2026
(11:59 PM EDT on May 28, 2026)

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SECOND FLOOR
105 PICCADILLY
LONDON, UNITED KINGDOM W1J 7NJ

*Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. The Company's complete proxy materials contain important information and are available online at www.ProxyVote.com. You are encouraged to access the proxy materials before voting. Please follow the instructions on the reverse side to vote these important matters.

| Voting Items | Board Recommends |
|--|---------------------|
| Ordinary Resolutions | |
| 1. Election of Class II Directors to serve until the 2029 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association. | |
| Nominees: | |
| 1a. Stephen R. Biggar | ✔ For |
| 1b. G. Bradley Cole | ✔ For |
| 1c. Barry D. Quart | ✔ For |
| 2. To approve the appointment of PricewaterhouseCoopers LLP (" PwC ") as the Company's UK statutory auditors until the close of the 2027 Annual General Meeting of Shareholders. | ✔ For |
| 3. To ratify the appointment of PwC as the Company's US independent registered public accounting firm for the fiscal year ending December 31, 2026. | ✔ For |
| 4. To authorize the Company's Board of Directors, through its Audit Committee, to determine PwC's remuneration in its capacity as our UK statutory auditors until the close of the 2027 Annual General Meeting of Shareholders. | ✔ For |
| 5. To receive the Company's UK statutory annual accounts and report for the period ended December 31, 2025. | ✔ For |
| 6. To approve, on an advisory (non-binding) basis, the Company's UK Statutory Directors' Annual Remuneration Report for the period ended December 31, 2025. | ✔ For |
| 7. To approve the Company's UK Statutory Directors' Remuneration Policy. | ✔ For |
| 8. To approve, on an advisory (non-binding) basis, the compensation of our named executive officers. | ✔ For |
| NOTE: At the Company's Annual General Meeting, the proxies have discretion to transact such other business as may properly come before the meeting or any continuation, postponement or adjournment thereof. | |

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".